CASE REPORT article
Front. Immunol.
Sec. T Cell Biology
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1593343
This article is part of the Research TopicBCL-2 Family Inhibitors in Hematologic MalignanciesView all 7 articles
Effective venetoclax treatment for indolent T-cell lymphoma of the gastrointestinal tract: A case report and literature review
Provisionally accepted
- 1Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong, China
- 2Qilu Hospital, Shandong University, Jinan, Shandong Province, China
- 3Shanghai Jiao Tong University School of Medicine, Shanghai, China
- 4First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi Province, China
- 5Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Indolent T-cell lymphoma of the gastrointestinal tract (iTCL-GI) is rare, lacking standardized treatments. We report a successful venetoclax treatment in one patient with indolent T-cell lymphoma of the gastrointestinal tract. A 35-year-old male was admitted due to complaints of anemia and hematochezia. He was diagnosed with iTCL-GI according to histopathology and next-generation sequencing (NGS). He received the first cycle of CHOP-E chemotherapy, but he continued to have intermittent blood in stools. After starting oral Bcl-2 inhibitor venetoclax, the results of peripheral hemogram and the body temperature gradually turned normal, with no symptoms of hematochezia occurring again. In addition, colonoscopy showed improved ulcers in the ascending and transverse colon. Routine blood tests returned to normal without adverse effects. Therefore, venetoclax may represent a potential treatment approach for iTCL-GI. This report might provide clues for the future management of similar cases.
Keywords: Indolent T-cell lymphoma, Gastrointestinal Tract, Hematochezia, venetoclax, B-cell lymphoma 2
Received: 13 Mar 2025; Accepted: 10 Jun 2025.
Copyright: © 2025 Jian, Hao, Yuan, Zhang, Huang and Du. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ji-Mo Jian, Qilu Hospital of Shandong University (Qingdao), Qingdao, 266035, Shandong, China
Jun Du, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200000, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.